/ Zydus Cadila Bags USFDA Approval For Budesonide Capsules ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Friday, 5 May 2017

Pharma major, Zydus Cadila also known as Cadila healthcare received the final approval from the US Food and Drugs Association (USFDA) to market the drug, Budesonide Capsules, 3mg. Budesonide Capsules are widely used for the treatment of mild to moderate active Crohn’s disease.

Recently the company also received the USFDA’s approval for the production of anti-hypertensive tablets and also an anti-cholestrol drug.

The company has over 110 approvals from the USFDA and has filled over 300 ANDAa till March, 2017.  

The stock of the company opened at Rs 456 and reached the intraday high of Rs 456 at 09:25 hrs IST. At 01:00 hrs IST, the pharma major’s stock was trading at RS 461.50, up by 0.80 per cent on the BSE, as on May 5, 2017. 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717